RALEIGH, N.C. , July 22, 2024 /PRNewswire/ -- Caidya, a leading global provider of clinical trial solutions, is pleased to announce a transition in its executive leadership.
Barbara Lopez Kunz , a distinguished member of the Caidya Board of Directors, will assume the role of Chief Executive Officer effective September 1, 2024 . The current Chairman and CEO, Dr. Lingshi Tan, will transition to Executive Chairman of the Board.
Barbara Lopez Kunz brings a wealth of experience to the role, having served in various leadership capacities across the healthcare and life sciences sectors. With over 15 years of C-suite experience and a proven track record in driving strategic partnerships and digital transformation, Ms. Kunz is well-prepared to lead Caidya into its next phase of growth and innovation.
Dr. Lingshi Tan expressed his enthusiasm for Ms. Kunz's appointment, stating, "Barbara's leadership capabilities and profound understanding of the global healthcare landscape have been invaluable to our board.
Her strategic vision and commitment to innovation have already significantly impacted our business. I have the utmost confidence in her ability to steer Caidya towards a successful future. I am thrilled she has accepted this expanded role and look forward to working closely with her.
" In her new role, Ms. Kunz will focus on enhancing Caidya's position as a global leader in clinical research, emphasizing the importance of patient-centered trials and building personalized, fit-for-pur.